Case-control study of the effects of pimobendan on survival time in cats with hypertrophic Cardiomyopathy and congestive heart failure

Yamir Reina-Doreste, Joshua A Stern, Bruce W. Keene, Sandra P. Tou, Clarke E. Atkins, Teresa C. Defrancesco, Marisa K. Ames, Timothy Hodge, Kathryn M. Meurs

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective-To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM). Design-Retrospective case-control study. Animals-27 cats receiving treatment with pimobendan and 27 cats receiving treatment without pimobendan. Procedures-Medical records between 2003 and 2013 were reviewed. All cats with HCM or HOCM treated with a regimen that included pimobendan (case cats) were identified. Control cats (cats with CHF treated during the same period with a regimen that did not include pimobendan) were selected by matching to case cats on the basis of age, sex, body weight, type of cardiomyopathy, and manifestation of CHF. Data collected included signalment, physical examination findings, echocardiographic data, serum biochemical values, and survival time from initial diagnosis of CHF. Kaplan-Meier survival curves were constructed and compared by means of a log rank test. Results-Cats receiving pimobendan had a significant benefit in survival time. Median survival time of case cats receiving pimobendan was 626 days, whereas median survival time for control cats not receiving pimobendan was 103 days. No significant differences were detected for any other variable. Conclusions and Clinical Relevance-The addition of pimobendan to traditional treatment for CHF may provide a substantial clinical benefit in survival time for HCM-affected cats with CHF and possibly HOCM-affected cats with CHF.

Original languageEnglish (US)
Pages (from-to)534-539
Number of pages6
JournalJournal of the American Veterinary Medical Association
Volume245
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Hypertrophic Cardiomyopathy
cardiomyopathy
heart failure
case-control studies
Case-Control Studies
Cats
Heart Failure
cats
pimobendan
Somatotypes
Kaplan-Meier Estimate
Cardiomyopathies
clinical examination
Physical Examination
Medical Records
Body Weight

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Case-control study of the effects of pimobendan on survival time in cats with hypertrophic Cardiomyopathy and congestive heart failure. / Reina-Doreste, Yamir; Stern, Joshua A; Keene, Bruce W.; Tou, Sandra P.; Atkins, Clarke E.; Defrancesco, Teresa C.; Ames, Marisa K.; Hodge, Timothy; Meurs, Kathryn M.

In: Journal of the American Veterinary Medical Association, Vol. 245, No. 5, 2014, p. 534-539.

Research output: Contribution to journalArticle

Reina-Doreste, Yamir ; Stern, Joshua A ; Keene, Bruce W. ; Tou, Sandra P. ; Atkins, Clarke E. ; Defrancesco, Teresa C. ; Ames, Marisa K. ; Hodge, Timothy ; Meurs, Kathryn M. / Case-control study of the effects of pimobendan on survival time in cats with hypertrophic Cardiomyopathy and congestive heart failure. In: Journal of the American Veterinary Medical Association. 2014 ; Vol. 245, No. 5. pp. 534-539.
@article{08c8aeb7a0ec4949b30fe0680aeaa4da,
title = "Case-control study of the effects of pimobendan on survival time in cats with hypertrophic Cardiomyopathy and congestive heart failure",
abstract = "Objective-To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM). Design-Retrospective case-control study. Animals-27 cats receiving treatment with pimobendan and 27 cats receiving treatment without pimobendan. Procedures-Medical records between 2003 and 2013 were reviewed. All cats with HCM or HOCM treated with a regimen that included pimobendan (case cats) were identified. Control cats (cats with CHF treated during the same period with a regimen that did not include pimobendan) were selected by matching to case cats on the basis of age, sex, body weight, type of cardiomyopathy, and manifestation of CHF. Data collected included signalment, physical examination findings, echocardiographic data, serum biochemical values, and survival time from initial diagnosis of CHF. Kaplan-Meier survival curves were constructed and compared by means of a log rank test. Results-Cats receiving pimobendan had a significant benefit in survival time. Median survival time of case cats receiving pimobendan was 626 days, whereas median survival time for control cats not receiving pimobendan was 103 days. No significant differences were detected for any other variable. Conclusions and Clinical Relevance-The addition of pimobendan to traditional treatment for CHF may provide a substantial clinical benefit in survival time for HCM-affected cats with CHF and possibly HOCM-affected cats with CHF.",
author = "Yamir Reina-Doreste and Stern, {Joshua A} and Keene, {Bruce W.} and Tou, {Sandra P.} and Atkins, {Clarke E.} and Defrancesco, {Teresa C.} and Ames, {Marisa K.} and Timothy Hodge and Meurs, {Kathryn M.}",
year = "2014",
doi = "10.2460/javma.245.5.534",
language = "English (US)",
volume = "245",
pages = "534--539",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "5",

}

TY - JOUR

T1 - Case-control study of the effects of pimobendan on survival time in cats with hypertrophic Cardiomyopathy and congestive heart failure

AU - Reina-Doreste, Yamir

AU - Stern, Joshua A

AU - Keene, Bruce W.

AU - Tou, Sandra P.

AU - Atkins, Clarke E.

AU - Defrancesco, Teresa C.

AU - Ames, Marisa K.

AU - Hodge, Timothy

AU - Meurs, Kathryn M.

PY - 2014

Y1 - 2014

N2 - Objective-To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM). Design-Retrospective case-control study. Animals-27 cats receiving treatment with pimobendan and 27 cats receiving treatment without pimobendan. Procedures-Medical records between 2003 and 2013 were reviewed. All cats with HCM or HOCM treated with a regimen that included pimobendan (case cats) were identified. Control cats (cats with CHF treated during the same period with a regimen that did not include pimobendan) were selected by matching to case cats on the basis of age, sex, body weight, type of cardiomyopathy, and manifestation of CHF. Data collected included signalment, physical examination findings, echocardiographic data, serum biochemical values, and survival time from initial diagnosis of CHF. Kaplan-Meier survival curves were constructed and compared by means of a log rank test. Results-Cats receiving pimobendan had a significant benefit in survival time. Median survival time of case cats receiving pimobendan was 626 days, whereas median survival time for control cats not receiving pimobendan was 103 days. No significant differences were detected for any other variable. Conclusions and Clinical Relevance-The addition of pimobendan to traditional treatment for CHF may provide a substantial clinical benefit in survival time for HCM-affected cats with CHF and possibly HOCM-affected cats with CHF.

AB - Objective-To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM). Design-Retrospective case-control study. Animals-27 cats receiving treatment with pimobendan and 27 cats receiving treatment without pimobendan. Procedures-Medical records between 2003 and 2013 were reviewed. All cats with HCM or HOCM treated with a regimen that included pimobendan (case cats) were identified. Control cats (cats with CHF treated during the same period with a regimen that did not include pimobendan) were selected by matching to case cats on the basis of age, sex, body weight, type of cardiomyopathy, and manifestation of CHF. Data collected included signalment, physical examination findings, echocardiographic data, serum biochemical values, and survival time from initial diagnosis of CHF. Kaplan-Meier survival curves were constructed and compared by means of a log rank test. Results-Cats receiving pimobendan had a significant benefit in survival time. Median survival time of case cats receiving pimobendan was 626 days, whereas median survival time for control cats not receiving pimobendan was 103 days. No significant differences were detected for any other variable. Conclusions and Clinical Relevance-The addition of pimobendan to traditional treatment for CHF may provide a substantial clinical benefit in survival time for HCM-affected cats with CHF and possibly HOCM-affected cats with CHF.

UR - http://www.scopus.com/inward/record.url?scp=84906568891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906568891&partnerID=8YFLogxK

U2 - 10.2460/javma.245.5.534

DO - 10.2460/javma.245.5.534

M3 - Article

C2 - 25148095

AN - SCOPUS:84906568891

VL - 245

SP - 534

EP - 539

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 5

ER -